189956-08-9

Upstream product

• 189955-79-1 2-bromo-2-methyl-1-[4-(methylsulfonyl)phenyl]propan-1-one 
• 516453-68-2 2-methyl-1-[4-(methylsulfonyl)phenyl]prop-2-en-1-one 

Downstream Products

• 189956-09-0 (R)-(4-Methanesulfonyl-phenyl)-((S)-2-methyl-oxiranyl)-methanol 
• 189954-93-6 (S)-5-ethyl-5-methyl-3-(1-methylethoxy)-4-[(4-methylsulfonyl)phenyl]-3-oxolen-2-one 
• 455878-44-1 (S)-1-ethyl-1-methyl-2-[(4-methylsulfonyl)phenyl]-2-oxoethyl 2-(1-methylethoxy)acetate 
• 189956-13-6 (S)-2-hydroxy-2-methyl-1-[4-(methylsulfonyl)phenyl]butan-1-one 
• 189956-10-3 (S)-2-[(R)-(1-Ethoxy-ethoxy)-(4-methanesulfonyl-phenyl)-methyl]-2-methyl-oxirane 
• 190966-58-6 (1R,2S)-1-(1-Ethoxy-ethoxy)-1-(4-methanesulfonyl-phenyl)-2-methyl-butan-2-ol 

Relevant academic research and scientific papers

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

The COX-2 inhibitor DFP [5,5-dimethyl-3-(2-propoxy)-4-methanesulfonylphenyl)-2(5H)-furanone] was found to have a long half-life in humans. Analogues have been characterized in order to optimize pharmacokinetics. This has lead to the discovery of 5(S)-(5-ethyl-5-methyl-3-(2-propoxy)-4-methanesulfonylphenyl)-2(5H)-furanone analogue 11 a potent and selective COX-2 inhibitor which is metabolized to a greater extent than DFP upon incubation with rat and human hepatocytes, suggesting a shorter half-life in humans.

(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.

3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.